ANIX · Anixa Biosciences, Inc.
Anixa Biosciences Inc (ANIX)
What's happening
- ANIX is down 1.28% today, trading at $3.09. — Live quote
- Volume today (205) is well below its 3-month average of 219,150. (Finnhub fundamentals)
- Reports earnings on 2026-09-08, 5 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.07 actual vs. $-0.09 estimated (+21.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-09-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Apr '26 | Jan '26 | Jul '25 | Apr '25 | Jan '25 |
|---|---|---|---|---|---|
| Market cap | $106.2M | $97.3M | $98.9M | $88.0M | $92.2M |
| P/E | -10.49 | -9.01 | -8.59 | -7.11 | -7.17 |
| Price/Book | 7.34 | 6.45 | 5.96 | 5.48 | 5.16 |
| ROE | -69.98% | -71.61% | -69.35% | -77.11% | -72.01% |
| ROA | -68.14% | -70.88% | -65.20% | -72.98% | -67.99% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +4.7%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -1090.5%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-08-03; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ANIX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Apr '26 | Jan '26 | Jul '25 | Apr '25 | Jan '25 | Jul '24 | Apr '24 | Jan '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$2.6M | -$2.7M | -$2.4M | -$3.0M | -$3.4M | -$3.6M | -$3.5M | -$3.6M |
| Net income | -$2.5M | -$2.6M | -$2.3M | -$2.8M | -$3.2M | -$3.3M | -$3.1M | -$3.3M |
| EPS (diluted) | $-0.07 | $-0.08 | $-0.07 | $-0.09 | $-0.10 | $-0.10 | $-0.10 | $-0.10 |
| EPS (basic) | $-0.07 | $-0.08 | $-0.07 | $-0.09 | $-0.10 | $-0.10 | $-0.10 | $-0.10 |
Balance sheet
| Line item | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $14.9M | $15.2M | $16.1M | $17.7M | $17.0M | $18.9M | $21.6M | $22.9M |
| Total liabilities | $1.6M | $1.4M | $2.1M | $2.2M | $2.1M | $2.2M | $2.7M | $2.2M |
| Stockholders' equity | $14.5M | $15.1M | $15.2M | $16.6M | $16.1M | $17.9M | $20.0M | $21.8M |
| Total current assets | $14.7M | $15.1M | $15.9M | $17.4M | $16.8M | $18.7M | $21.4M | $22.7M |
| Total current liabilities | $1.5M | $1.2M | $2.0M | $2.1M | $1.9M | $2.0M | $2.5M | $2.0M |
| Cash & equivalents | $1.5M | $1.5M | $1.2M | $1.5M | $1.9M | $1.1M | $1.3M | $1.2M |
| Marketable securities (current) | $12.2M | $12.7M | $13.9M | $14.5M | $13.7M | $16.2M | $18.7M | $19.5M |
| Accounts receivable | $56.0K | — | — | — | — | — | $173.0K | $410.0K |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Accounts payable | $252.0K | $148.0K | $165.0K | $276.0K | $284.0K | $600.0K | $525.0K | $302.0K |
| Accrued liabilities | $1.2M | $1.0M | $1.8M | $1.8M | $1.6M | $1.4M | $1.9M | $1.7M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $339.0K | $335.0K | $330.0K | $328.0K | $322.0K | $322.0K | $322.0K | $321.0K |
| Retained earnings | -$256.8M | -$254.2M | -$251.7M | -$249.0M | -$246.7M | -$243.9M | -$240.8M | -$237.9M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.7M | -$2.6M | -$1.3M | -$1.5M | -$1.5M | -$2.9M | -$927.0K | -$2.6M |
| Investing cash flow | $422.0K | $1.2M | $654.0K | -$833.0K | $2.3M | $2.7M | $867.0K | $2.7M |
| Financing cash flow | $1.2M | $1.7M | $350.0K | $1.9M | $18.0K | -$17.0K | $106.0K | $149.0K |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Share-based compensation | $637.0K | $768.0K | $859.0K | $829.0K | $962.0K | $1.0M | $980.0K | $1.1M |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in inventory | — | — | — | — | — | — | — | — |
| Change in accounts payable | $104.0K | -$17.0K | -$111.0K | -$8.0K | -$316.0K | $75.0K | $223.0K | $87.0K |
| Other investing activities | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | $6.0K | — |
Income statement
| Line item | Oct '25 | Oct '24 | Oct '23 | Oct '22 | Oct '21 |
|---|---|---|---|---|---|
| Revenue | — | $210.0K | $210.0K | — | $512.0K |
| Operating income | -$11.7M | -$13.8M | -$11.0M | -$13.9M | -$13.1M |
| Net income | -$10.9M | -$12.6M | -$9.8M | -$13.6M | -$13.0M |
| EPS (diluted) | $-0.34 | $-0.39 | $-0.32 | $0.45 | — |
| EPS (basic) | $-0.34 | $-0.39 | $-0.32 | $0.45 | $-0.45 |
| Operating margin | — | -$6.6K | -$5.2K | — | -$2.6K |
| Net margin | — | -$6.0K | -$4.7K | — | -$2.5K |
Balance sheet
| Line item | Oct '25 | Oct '24 | Oct '23 | Oct '22 | Oct '21 |
|---|---|---|---|---|---|
| Total assets | $16.1M | $21.6M | $25.5M | $30.4M | $36.3M |
| Total liabilities | $2.1M | $2.7M | $2.2M | $2.2M | $1.5M |
| Stockholders' equity | $15.2M | $20.0M | $24.3M | $29.0M | $35.4M |
| Total current assets | $15.9M | $21.4M | $25.4M | $30.2M | $36.0M |
| Total current liabilities | $2.0M | $2.5M | $2.0M | $2.0M | $1.3M |
| Cash & equivalents | $1.2M | $1.3M | $915.0K | $12.4M | $29.1M |
| Marketable securities (current) | $13.9M | $18.7M | $22.9M | $17.3M | $6.6M |
| Accounts receivable | — | $173.0K | $270.0K | $46.0K | — |
| Property, plant & equipment | — | — | — | — | — |
| Accounts payable | $165.0K | $525.0K | $206.0K | $265.0K | $136.0K |
| Accrued liabilities | $1.8M | $1.9M | $1.8M | $1.7M | $1.1M |
| Deferred revenue (current) | — | — | — | — | — |
| Long-term debt | — | — | — | — | — |
| Common stock & paid-in capital | $330.0K | $322.0K | $311.0K | $309.0K | $301.0K |
| Retained earnings | -$251.7M | -$240.8M | -$228.2M | -$218.4M | -$204.8M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — |
Cash flow
| Line item | Oct '25 | Oct '24 | Oct '23 | Oct '22 | Oct '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$7.2M | -$7.3M | -$6.2M | -$6.5M | -$4.9M |
| Investing cash flow | $4.9M | $4.3M | -$5.6M | -$10.7M | -$3.9M |
| Financing cash flow | $2.3M | $3.4M | $366.0K | $452.0K | $31.6M |
| Capital expenditures | — | — | — | — | — |
| Share-based compensation | $3.7M | $4.4M | $4.4M | $6.0M | $7.5M |
| Change in accounts receivable | — | — | — | — | — |
| Change in accounts payable | -$360.0K | $319.0K | -$59.0K | $129.0K | -$96.0K |
| Other investing activities | — | — | — | — | — |
| Share repurchases | — | $6.0K | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ANIX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 11:50 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-03 | 4 | 2026-07-31 | View on SEC.gov → |
| 2026-07-29 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-28 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-27 | 4 | 2026-07-27 | View on SEC.gov → |
| 2026-07-27 | 4 | 2026-07-24 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-20 | View on SEC.gov → |
| 2026-07-20 | 4 | 2026-07-20 | View on SEC.gov → |
| 2026-07-16 | 4 | 2026-07-15 | View on SEC.gov → |
| 2026-07-13 | 4 | 2026-07-10 | View on SEC.gov → |
| 2026-06-17 | 4 | 2026-06-16 | View on SEC.gov → |
| 2026-06-16 | 4 | 2026-06-12 | View on SEC.gov → |
| 2026-06-10 | 10-Q | 2026-04-30 | View on SEC.gov → |
Recent news
Headlines about ANIX (Anixa Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Yahoo Finance · 2026-09-03 -
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Yahoo Finance · 2026-08-24 -
Anixa Biosciences To Present Data On Its Breast Cancer Vaccine At 2026 Cantor Fitzgerald Global Healthcare Conference
Benzinga · 2026-08-24 -
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance · 2026-08-18 -
Anixa Biosciences secures Korean patent for breast cancer vaccine
Yahoo Finance · 2026-06-30 -
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Yahoo Finance · 2026-06-29 -
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Yahoo Finance · 2026-06-26 -
/C O R R E C T I O N -- Anixa Biosciences, Inc./
Yahoo Finance · 2026-05-11
No headlines in this category right now — try “All”.